Table 1 Baseline characteristics of systemic AL amyloidosis patients.
Characteristic | Systemic AL amyloidosis (n = 575) |
|---|---|
Male—n (%) | 370 (64) |
Female—n (%) | 205 (36) |
Concomitant symptomatic multiple myeloma—n (%) | 45 (8) |
Amyloid light chain subtype | |
Kappa—n (%) | 169 (24) |
Lambda—n (%) | 406 (71) |
Organ involvement at diagnosis | |
Renal—n (%) | 394 (69) |
Cardiac—n (%) | 306 (53) |
Peripheral or autonomic neuropathy—n (%) | 105 (18) |
GI—n (%) | 89% (15) |
Liver—n (%) | 66 (11) |
At diagnosis | |
Median 24 h urine proteinuria—mg (IQR) | 2168 (808–5795) |
Median urine monoclonal protein—mg (IQR) | 0 (0–175) |
Median serum creatinine—mg/dL (IQR) | 1.1 (0.9–1.5) |
Median dFLC at diagnosis—mg/L (IQR)a | 188 (68–551) |
dFLC < 10 mg/L—n (%) | 28 (5) |
dFLC > 1000 mg/L—n (%) | 42 (7) |
Bone marrow plasma cell burden—% (IQR) | 10 (5–19) |
At urine collection | |
Age—years (IQR) | 65 (59–71) |
Median UACR—mg/g (IQR) | 211 (19–2516) |
Median spot urine albumin—mg/L (IQR) | 170 (17–2129) |
Median 24 h urine proteinuria—mg (IQR) | 447 (141–3059) |
Median eGFR—mL/min/1.73m2 (IQR)b | 57 (34–74) |
Median time between 24hUP and uACR—days (IQR) | 0 (0–1) |
Median time between diagnosis and uACR collection—months (IQR) | 24 (0.9–77) |
AM (before noon) UACR collection time—n (%) | 346 (60) |
PM (after noon) UACR collection time—n (%) | 229 (40) |
BMI—kg/m2 (IQR) | 26.1 (23.4–29.7) |
